Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Net Cash Flow: 2022-2025

Historic Net Cash Flow for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to -$11.8 million.

  • Corvus Pharmaceuticals' Net Cash Flow fell 16.37% to -$11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 96.04%. This contributed to the annual value of -$3.9 million for FY2024, which is 619.85% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Net Cash Flow stood at -$11.8 million for Q3 2025, which was down 222.00% from $9.7 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Net Cash Flow high stood at $12.4 million for Q3 2023, and its period low was -$32.0 million during Q1 2022.
  • Over the past 3 years, Corvus Pharmaceuticals' median Net Cash Flow value was -$3.7 million (recorded in 2025), while the average stood at -$3.7 million.
  • In the last 5 years, Corvus Pharmaceuticals' Net Cash Flow surged by 420.06% in 2023 and then tumbled by 1,051.55% in 2024.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Net Cash Flow stood at -$11.4 million in 2022, then spiked by 34.51% to -$7.5 million in 2023, then spiked by 154.24% to $4.1 million in 2024, then declined by 16.37% to -$11.8 million in 2025.
  • Its Net Cash Flow was -$11.8 million in Q3 2025, compared to $9.7 million in Q2 2025 and -$3.7 million in Q1 2025.